X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

ANNX

Closed

Annexon inc

2.47
+0.07 (+2.92%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.4
Day's Range: 2.3 - 2.53
Send
When Written:
 
3.85
Annexon Inc is a biopharmaceutical company that develops therapies for patients with classical complement-mediated disorders. The company's lead product candidate, ANX005, is a monoclonal antibody that targets C1q, a protein in the complement system that plays a key role in autoimmune and neurodegenerative diseases. Annexon was founded in 2011 and is headquartered in South San Francisco, California. The company has raised over $300 million in funding from investors such as New Enterprise Associates, Novartis Venture Fund, and Blackstone Life Sciences. Annexon has also entered into partnerships with pharmaceutical companies such as Takeda and Celgene.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X